Adenovirus formulations

Details Adenovirus formulations Adenovirus formulations

2005-03-03

2008-11-25

Mosher, Mary E (Department: 1648)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

C424S199100, C424S233100, C424S093200

Reexamination Certificate

active

07456009

ABSTRACT:
The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.

REFERENCES:
patent: 5932223 (1999-08-01), Burke et al.
patent: 6039958 (2000-03-01), Koyama et al.
patent: 6225289 (2001-05-01), Kovesdi et al.
patent: 6514943 (2003-02-01), Kovesdi et al.
patent: 6635476 (2003-10-01), Murphy
patent: 6689600 (2004-02-01), Wu et al.
patent: 6730328 (2004-05-01), Maskiewicz et al.
patent: 2002/0031527 (2002-03-01), Wu et al.
patent: 2004/0166122 (2004-08-01), Evans et al.
patent: WO 98/02522 (1998-01-01), None
patent: WO 99/41416 (1999-08-01), None
patent: WO 99/45841 (1999-09-01), None
patent: WO 00/45841 (2000-08-01), None
patent: WO 01/66137 (2001-09-01), None
Kanegae et al., “A simple and efficient method for purification of infectious recombinant adenovirus,” Jpn J Med Sci Biol, 47(3), pp. 157-166 (1994).
Bruzzone et al., “Specific Subgroup B Adenovirus Diagnosis by PCR of the Fibre Gene,” Journal of Infection, 40, pp. 154-159 (2000).
Chanock, R. et al. “Immunization by Selective Infection With Type 4 Adenovirus Grown in Human Diploid Tissue Culture”, Journal American Medical Association, 1966, vol. 195, pp. 151-158.
Griffin, J. et al. “Live and Inactivated Adenovirus Vaccines”, Arch. Intern. Med., 1970, vol. 125, pp. 981-986.
Top, F. et al. “Immunization with Live Type 7 and 4 Adenovirus Vaccines. I. Safety, Infectivity, Antigenicity, and Potency of Adenovirus Type 7 Vaccine in Humans”, The Journal of Infectious Diseases, 1971, vol. 124, pp. 148-154.
Nyberg-Hoffman, C. et al. “Instability of adenoviral vectors during transport and its implication for clinical studies”, Nature Medicine, 1999, vol. 5, pp. 955-957.
Croyle, M. et al. “Factors That Influence Stability of Recombinant Adenoviral Preparations for Human Gene Therapy”, Pharmaceutical Development and Technology, 1998, vol. 3, pp. 373-383.
Ermilov, A. et al. “Culture media and their components differ in their ability to scavenge reactive oxygen species in the plasmid relaxation assay”, Fertility and Sterility, 1999, vol. 72, pp. 154-157.
Robert K. Evans et al. “Evaluation of Degradation Pathways for Plasmid DNA in Pharmaceutical Formulations via Accelerated Stability Studies”, Journal of Pharmaceutical Sciences, vol. 89, No. 1, Jan. 2000, pp. 76-87.

Affiliated with

Also associated with

Rating

Adenovirus formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adenovirus formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4025749